Monthly Archives: November 2017

In Search Of Novelty: 2017’s New FDA Drug Approvals
November 30, 2017

It’s been an exciting year for new drug approvals, with the FDA on a similar pace to the gangbuster year of 2015. Many of these new medicines address significant and meaningful needs, or offer additional therapeutic choices for patients and

Leave a comment

Brexit – Own Goal Or Overhead Kick?
November 27, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On June 27, 2016 England’s soccer team was knocked out of the European Championships by Iceland – a tiny

1 Comment

Painful Truth: Successful Failure Of A Biotech Startup
November 17, 2017

Back in the summer, I got the call that no biotech venture investor wants to get. On the morning of August 8th, I received an urgent text of “can you talk now?” quickly followed with a call. I learned then


Living Medicines With Curative Intent: Small N’s Go Viral
November 7, 2017

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell

Leave a comment